Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Silybin phytosome

Silybin Phytosome (Siliphos) · also known as Silybin, Siliphos, Silymarin phospholipid complex

Silybin is one of the main active compounds in milk thistle and is a flavonolignan. Animal studies show it can upregulate Nrf2 target genes, and it has antioxidant activity in vitro. In humans, none of the proposed mechanisms (acting on Nrf2 targets, direct free-radical scavenging, promoting tissue repair) has been confirmed.

Typical dose: Silybin phospholipid complex 120–360 mg/day, taken with a meal
Absorption and forms: Ordinary silymarin is poorly soluble in both water and fat, and its oral bioavailability has been reported at below 2%. A 1:2 phospholipid complex with soy lecithin (Siliphos) can raise plasma exposure, reportedly by nearly 10-fold. The size of the increase depends on the formulation, the dose, and whether conjugated metabolites are measured, so it should not be treated as a fixed figure.

Clinical uses and human evidence

Fatty liver and liver enzymes

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Loguercio 2012 · Free Radic Biol Med · RCT · n=179 — Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial

Blood sugar and insulin resistance

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Loguercio 2012 · Free Radic Biol Med · RCT · n=179 — Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial

All-cause mortality risk

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Rambaldi 2007 · Cochrane Database Syst Rev · Meta-analysis · n=1088 — Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases

Mechanisms of action

Nrf2/ARE activation of endogenous antioxidant enzymes

★★★☆☆Mechanism evidence: grade CSecondary target

In an animal model of steatohepatitis, oral silybin increased expression of Nrf2 target genes, which supports modulation of this pathway. However, a direct change in Keap1 conformation and induction of GST and HO-1 in the human liver have not been confirmed.

References (1)
  1. Ou 2018 · Mouse study: after oral silybin, Nrf2 target gene expression rose in a steatohepatitis model

Epithelial tight junction (ZO-1 / Occludin) reinforcement and barrier repair

★★☆☆☆Mechanism evidence: grade CSecondary target

In mouse intestinal barrier studies, silybin-associated changes in the gut microbiota were accompanied by upregulation of tight junction proteins. This is not the same as improved liver microcirculation or a better bile duct epithelial barrier. Tight junction repair in humans after taking the phospholipid complex orally has not been directly shown.

References (1)
  1. 2023 · Mouse study: silybin-associated changes in the gut microbiota were accompanied by upregulation of tight junction proteins

Direct free radical trapping and chemical quenching

★★☆☆☆Mechanism evidence: grade DSecondary target

Silybin has antioxidant activity in vitro, and oxidative stress markers improved in an animal model of steatohepatitis, but these changes were accompanied by changes in several signaling pathways. Whether it directly intercepts lipid peroxidation chain reactions within membranes, and how much it contributes to direct scavenging after oral dosing in humans, both remain unclear.

References (1)
  1. Ou 2018 · Mouse study: oxidative stress markers improved, alongside changes in several signaling pathways

Safety and drug interactions

Use with caution in people with complete mechanical obstruction of the bile ducts, because silybin has a mild choleretic effect. Generally well tolerated at usual doses.
Open in the interactive app ›